Evidence map›Paper›PMID 24648000›Full record

ArticleJournal of nephrology2014

Wild-type uromodulin prevents NFkB activation in kidney cells, while mutant uromodulin, causing FJHU nephropathy, does not.

Dganit Dinour, Liat Ganon, Levin-Iaina Nomy, Rotem Ron, Eliezer J Holtzman

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dganit DinourDepartment of Nephrology and Hypertension, The Chaim Sheba Medical Center, Tel-Hashomer and the Faculty of Medicine, Sackler School of Medicine, Sheba Medical Center, 52621, Tel-Aviv, Israel, Dganit.Dinour@sheba.health.gov.il.
Liat Ganon
Levin-Iaina Nomy
Rotem Ron
Eliezer J Holtzman
Sheba Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUromodulin (Tamm-Horsfall protein) is the most abundant urinary protein in healthy individuals. Despite 60 years of research, its physiological role remains rather elusive. Familial juvenile hyperuricemic nephropathy and medullary cystic kidney disease Type 2 are autosomal dominant tubulointerstitial nephropathies characterized by gouty arthritis and progressive renal insufficiency, caused by uromodulin (UMOD) mutations. The aim of this study was to compare the cellular effects of mutant and wild-type UMOD.

methodsWild-type UMOD cDNA was cloned from human kidney cDNA into pcDNA3 expression vector. A mutant UMOD construct, containing the previously reported mutation, V273, was created by in vitro mutagenesis. Transient and stable transfection studies were performed in human embryonic kidney cells and mouse distal convoluted tubular cells, respectively. Expression was evaluated by reverse transcription polymerase chain reaction (RT-PCR), western blot and immunofluorescence. Oligosaccharide cleavage by glycosidases was performed to characterize different forms of UMOD. Nuclear translocation of P65 and degradation of IκBα and IRAK1 in response to interleukin (IL)-1β were used to evaluate the effects of wild-type and mutant UMOD on the IL-1R-NFκB pathway.

resultsThe mutant protein was shown to be retained in the endoplasmic reticulum and was not excreted to the cell medium, as opposed to the wild-type protein. NFκB activation in cells expressing mutant UMOD was similar to that of untransfected cells. In contrast, cells over-expressing wild-type UMOD showed markedly reduced NFκB activation.

conclusionOur findings suggest that UMOD may have a physiologic function related to its inhibitory effect on the NFκB pathway.

Indexed as

MutationActive Transport, Cell NucleusAnimalsEndoplasmic ReticulumGoutHEK293 CellsHumansHyperuricemiaI-kappa B ProteinsInterleukin-1betaInterleukin-1 Receptor-Associated KinasesKidneyKidney DiseasesMiceNF-KappaB Inhibitor alphaSignal TransductionI-kappa B ProteinsIL1B protein, humanInterleukin-1betaInterleukin-1 Receptor-Associated KinasesIRAK1 protein, humanNF-KappaB Inhibitor alphaNFKBIA protein, humanNfkbia protein, mouseRELA protein, humanTranscription Factor RelAUMOD protein, humanUromodulin

Identifiers

PMID24648000
OpenAlexW1971658813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.